ANALYSIS OF INTRAHEPATIC CYTOKINE EXPRESSION OF CHRONIC HCV-INFECTED PATIENTS ACCORDING TO RESPONSE TO INTERFERON THERAPY

被引：0
|
作者：
GAWECO, AS
VANTHIEL, DH
RUSTGI, V
OTTO, HF
SCHNEIDER, F
HOFMANN, WJ
机构：
[1] UNIV HEIDELBERG, INST PATHOL, W-6900 HEIDELBERG, GERMANY
[2] OKLAHOMA TRANSPLANTAT INST, OKLAHOMA CITY, OK USA
[3] INOVA INST, FALLS CHURCH, VA USA
来源：
GASTROENTEROLOGY | 1995年 / 108卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A1070 / A1070
页数：1
相关论文
共 50 条
  • [31] Expression of tumor suppressor PTPRD is downregulated in HCV-infected primary human hepatocytes and liver tissue of patients with chronic HCV infection
    Ababsa, Amina
    Duong, Francois H.
    Gondeau, Claire
    Heim, Markus H.
    Baumert, Thomas F.
    Lupberger, Joachim
    HEPATOLOGY, 2014, 60 : 1063A - 1064A
  • [32] Hepatic chemokine and cytokine gene profiling in chronic HCV-infected patients rentals a selective inducible protein (IP)-10/interferon-gamma expression that correlates with liver disease activity.
    Rico, MA
    Ruiz, S
    Quiroga, JA
    Pardo, M
    Carreno, V
    HEPATOLOGY, 2002, 36 (04) : 274A - 274A
  • [33] Exposure-Response Analysis for Efficacy of Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV-Infected Patients
    Ueno, T.
    Osawa, M.
    Shiozaki, T.
    Green, M.
    Garimella, T.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (07): : 903 - 913
  • [34] Uptake of interferon-free DAA therapy among HCV-infected decompensated cirrhosis patients and evidence for decreased mortality
    McDonald, Scott A.
    Barclay, Stephen T.
    Innes, Hamish A.
    Fraser, Andrew
    Hayes, Peter C.
    Bathgate, Andrew
    Dillon, John F.
    Went, April
    Goldberg, David J.
    Hutchinson, Sharon J.
    JOURNAL OF VIRAL HEPATITIS, 2021, 28 (09) : 1246 - 1255
  • [35] Epigenetic Analysis of the IFNλ3 Gene Identifies a Novel Marker for Response to Therapy in HCV-infected Subjects
    Waring, Jeffrey F.
    Dumas, Emily
    Coakley, Eoin
    Cohen, Daniel E.
    Idler, Kenneth B.
    Das, Ujjwal
    Podsadecki, Thomas
    Dutta, Sandeep
    HEPATOLOGY, 2014, 60 : 312A - 313A
  • [36] Open-label study of omega interferon in previously untreated HCV-infected patients
    Plauth, MM
    Meisel, H
    Langecker, P
    Moran, M
    Lang, W
    Blanchett, D
    Jetschmann, JU
    Brack, J
    Von Wussow, P
    JOURNAL OF HEPATOLOGY, 2002, 36 : 125 - 125
  • [37] Decrease of renal function in HCV and HIV/HCV-infected patients with telaprevir-based therapy
    Prinapori, Roberta
    Ricci, Elena
    Menzaghi, Barbara
    Borghi, Vanni
    Maggi, Paolo
    Martinelli, Canio
    Magni, Carlo
    Parruti, Giustino
    Bonfanti, Paolo
    Mussini, Cristina
    Di Biagio, Antonio
    AIDS, 2015, 29 (15) : 2061 - 2062
  • [38] SILIBININ AS A RESCUE TREATMENT HCV-INFECTED PATIENTS SHOWING SUBOPTIMAL VIROLOGIC RESPONSE TO STANDARD COMBINATION THERAPY
    Biermer, M.
    Stoehr, L.
    Schlosser, B.
    Fueloep, B.
    van Boemmel, F.
    Berg, T.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S16 - S16
  • [39] Pattern of HCV antibodies with special reference to NS5A reactivity in HCV-infected patients: relation to viral genotype, cryoglobulinemia and response to interferon
    Frangeul, L
    Cresta, P
    Perrin, M
    Duverlie, G
    Khorsi, H
    Musset, L
    Opolon, P
    Huraux, JM
    Lunel, F
    JOURNAL OF HEPATOLOGY, 1998, 28 (04) : 538 - 543
  • [40] Increased risk of carcinoma in chronic HCV-infected patients with latent HBV infection
    Nature Clinical Practice Gastroenterology & Hepatology, 2007, 4 (9): : 476 - 476
12345